Last reviewed · How we verify
Placebo (for denosumab)
Placebo has no active pharmacological mechanism and serves as an inert control comparator in clinical trials.
Placebo has no active pharmacological mechanism and serves as an inert control comparator in clinical trials. Used for Control arm in denosumab clinical trials.
At a glance
| Generic name | Placebo (for denosumab) |
|---|---|
| Also known as | Prefilled syringe of 1 mL placebo solution |
| Sponsor | Turku University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inactive substance used in randomized controlled trials to establish baseline efficacy and safety of an active drug (in this case, denosumab) through comparison against a non-therapeutic control. It allows researchers to distinguish true drug effects from natural disease progression, spontaneous remission, and placebo response effects.
Approved indications
- Control arm in denosumab clinical trials
Common side effects
Key clinical trials
- NAPO - Novel Approach for Oligospermia (PHASE1, PHASE2)
- RANKL Inhibition and Mammographic Breast Density (PHASE2)
- Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2) (PHASE4)
- Denosumab for Type 1 Diabetes (PHASE1, PHASE2)
- Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (PHASE3)
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI (PHASE2)
- Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients (PHASE2)
- DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for denosumab) CI brief — competitive landscape report
- Placebo (for denosumab) updates RSS · CI watch RSS
- Turku University Hospital portfolio CI